1. An ophthalmic composition comprising at least one angiotensin converting enzyme inhibitor (ACE) and a pharmaceutically acceptable carrier for use as an ophthalmic neuroprotective agent in the treatment of optic neuropathy or congenital optic atrophy. The ophthalmic composition according to claim 1, characterized in that said at least one angiotensin converting enzyme (ACE) inhibitor is fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, hinapril, enalapril, perindopril, benazepril, and mixtures thereof. The ophthalmic composition according to claim 1, characterized in that said at least one angiotensin converting enzyme (ACE) inhibitor is an active metabolite of fosinopril, ramipril, captopril, trandolapril, moexipril, lisinopril, hinapril, enalapril, perindopril and benaz . Ophthalmic composition according to claim 1, characterized in that said at least one angiotensin converting enzyme (ACE) inhibitor is fosinoprilat, trandolaprilat, moexiprilat, ramiprilat, quinaprilat, enalaprilat, perindoprilat and benazeprilat. 5. The ophthalmic composition according to claim 1, characterized in that said optic neuropathy is selected from the group including: congenital optic nerve atrophy, ischemic optic nerve neuropathy, inflammatory optic neuropathy, optic neuropathy, optic neuropathy, infiltrative optic neuropathy, optic neuropathy , mitochondrial optic neuropathy, food1. Офтальмологическая композиция, содержащая по меньшей мере один ингибитор ангиотензинпревращающего фермента (АПФ) и фармацевтически приемлемый носитель для применения в качестве офтальмологического нейропротектора в лечении нейропатии зрительного нерва или врожденной атрофии зрительного нерва.2. Офтальмологическая композиция по п. 1, отличающаяся тем, что указанный по меньшей мере один ингибитор ангиотензинпревращающего фермента (АПФ) представляет собой фозиноприл, рамиприл, каптоприл, трандолаприл, моэксиприл, лизиноприл, хинаприл, эналаприл, периндоприл, беназеприл и их смеси.3. Офта
